Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York 10032.
Department of Urology, Columbia Medical Center, New York, New York 10032.
Cold Spring Harb Perspect Med. 2019 May 1;9(5):a030627. doi: 10.1101/cshperspect.a030627.
Immunotherapy with agents that block immune checkpoints is a mainstay of therapy for several common tumor types; so far, prostate cancer is not among those treated using this method. The observed lack of activity in prostate cancer is not due to a lack of testing; several agents have been evaluated both alone and in combination. Although several combination strategies show some promise, it appears likely that a greater understanding of the prostate cancer tumor microenvironment and baseline immune response will be required to optimize future treatment strategies.
免疫疗法中使用的药物可以阻断免疫检查点，这是几种常见肿瘤类型的主要治疗方法；到目前为止，前列腺癌还没有采用这种方法进行治疗。在前列腺癌中观察到的这种药物缺乏活性并不是因为缺乏测试；已经评估了几种单独使用和联合使用的药物。尽管几种联合策略显示出了一定的前景，但似乎需要更深入地了解前列腺癌肿瘤微环境和基线免疫反应，以优化未来的治疗策略。
